Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients

INTRODUCTION: Carboplatin (CBDCA) administered at a dosage of 4 mg/mL/min or more area under the blood concentration-time curve (AUC) is considered to be ranked as the highest chemotherapy-induced nausea and vomiting (CINV) risk of the moderately emetogenic chemotherapy agents. The complete response...

Descripción completa

Detalles Bibliográficos
Autores principales: Iihara, Hirotoshi, Shimokawa, Mototsugu, Abe, Masakazu, Hayasaki, Yoh, Fujita, Yukiyoshi, Nagasawa, Yuki, Sakurai, Michiru, Matsuoka, Rie, Suzuki, Akio, Morishige, Kenichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340435/
https://www.ncbi.nlm.nih.gov/pubmed/30782732
http://dx.doi.org/10.1136/bmjopen-2018-024357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340435/
https://www.ncbi.nlm.nih.gov/pubmed/30782732
http://dx.doi.org/10.1136/bmjopen-2018-024357

Ejemplares similares